M A D'Hallewin1, L Baert. 1. Department of Urology, St. Pieter University Hospital, Catholic University of Leuven, Belgium.
Abstract
PURPOSE: We analyzed the value of the Bard bladder tumor antigen (BTA*) test for the diagnosis of stage Ta superficial bladder cancer and carcinoma in situ, and compared it to the highly sensitive bladder washing cytology. MATERIALS AND METHODS: The BTA test is a latex agglutination test that qualitatively detects the presence of basement membrane complexes in the urine. A total of 60 patients with superficial bladder cancer underwent voided urine BTA analysis and bladder washing cytologies. RESULTS: Of the patients 65% were correctly diagnosed with the BTA test compared to 32% with bladder washings, which is statistically significant (p < 0.001). CONCLUSIONS: The BTA test is a noninvasive diagnostic tool that is superior to bladder washing cytology for diagnosing superficial bladder cancer.
PURPOSE: We analyzed the value of the Bard bladder tumor antigen (BTA*) test for the diagnosis of stage Ta superficial bladder cancer and carcinoma in situ, and compared it to the highly sensitive bladder washing cytology. MATERIALS AND METHODS: The BTA test is a latex agglutination test that qualitatively detects the presence of basement membrane complexes in the urine. A total of 60 patients with superficial bladder cancer underwent voided urine BTA analysis and bladder washing cytologies. RESULTS: Of the patients 65% were correctly diagnosed with the BTA test compared to 32% with bladder washings, which is statistically significant (p < 0.001). CONCLUSIONS: The BTA test is a noninvasive diagnostic tool that is superior to bladder washing cytology for diagnosing superficial bladder cancer.
Authors: A S Protheroe; R E Banks; M Mzimba; W H Porter; J Southgate; P N Singh; M Bosomworth; P Harnden; P H Smith; P Whelan; P J Selby Journal: Br J Cancer Date: 1999-04 Impact factor: 7.640